CD4+ T Cells

  • Frederick J. Kohlhapp
  • Andrew Zloza
Reference work entry


CD4+ T cells are components of the adaptive immune system that have a diverse repertoire of functions, which are defined by the production of specific cytokines and expression of distinct intracellular transcription factors and surface chemokine receptors. The functional diversity of T cells is demonstrated by the association of certain CD4+ T cell types (including Th1 CD4+ T cells) with positive cancer prognosis and other CD4+ T cell types (including T regulatory and Th2 CD4+ T cells) with a negative cancer prognosis. While the presence of CD4+ T cell subtypes correlates with tumor progression, the precise role of CD4+ T cells in such progression remains uncertain based on the indirect role that CD4+ T cells often play in helping or suppressing other immune cell types (including CD8+ T cells, dendritic cells, NK cells, and myeloid-derived suppressor cells). Clinical therapies focusing on generating anti-tumor CD4+ T cell responses have been met with limited success. However, new approaches including Chimeric Antigen Receptors (CARs) may be increase the viability of CD4+ T cells as a potential therapeutic modality in the treatment of cancer.


CD4+ T cells Adoptive transfer Clinical monitoring Evaluation Prognosis Subsets Therapy Tumor progression Types Unique aspect of Major histocompatibility complex II (MHC-II) Regulatory T cells T cell receptor (TCR) T follicular helper (Tfh) T helper 1 (Th1) cells T helper 17 (Th17) cells T helper 2 (Th2) cells T helper 22 (Th22) cells T helper 9 (Th9) cells 


  1. Aarntzen EH et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013;73(1):19–29.Google Scholar
  2. Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014 Jul;11(7):413–31.Google Scholar
  3. Antony PA, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174(5):2591–601.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Arstila TP, et al. A direct estimate of the human alphabeta T cell receptor diversity. Science. 1999;286(5441):958–61.CrossRefPubMedGoogle Scholar
  5. Barrett DM et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65:333–47.Google Scholar
  6. Bindea G et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95.Google Scholar
  7. Clay TM, et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res. 2001;7(5):1127–35.PubMedGoogle Scholar
  8. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22(3):333–40.Google Scholar
  9. Fridman WH et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.Google Scholar
  10. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.CrossRefPubMedGoogle Scholar
  11. Gu-Trantien C et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873–92.Google Scholar
  12. Hunder NN, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698–703.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531–64.Google Scholar
  14. Kalos M. Biomarkers in T cell therapy clinical trials. J Transl Med. 2011;9:138.Google Scholar
  15. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60.Google Scholar
  16. Kenter GG, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838–47.CrossRefPubMedGoogle Scholar
  17. Kitano S et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013;1(4):235–44.Google Scholar
  18. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233–58.CrossRefPubMedGoogle Scholar
  19. Liu T et al. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J Clin Immunol. 2012;32(6):1332–9.Google Scholar
  20. Macchia I, Urbani F, Proietti E. Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays. Biomed Res Int. 2013:726239.Google Scholar
  21. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8(5):351–60.CrossRefPubMedGoogle Scholar
  22. Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Blood. 2013;121(13):2402–14.Google Scholar
  23. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009;21(2):200–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol. 2004;4(2):123–32.CrossRefPubMedGoogle Scholar
  25. Protti MP, Monte LD, Lullo GD. Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. Tissue Antigens. 2015;83(4):237–46.Google Scholar
  26. Qin S et al. Th22 cells are associated with hepatocellular carcinoma development and progression. Chin J Cancer Res. 2014;26(2):135–41.Google Scholar
  27. Quezada SA et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207(3):637–50.Google Scholar
  28. Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother. 2013;62(3):405–10.Google Scholar
  29. Robins H. Immunosequencing: applications of immune repertoire deep sequencing. Curr Opin Immunol. 2013;25(5):646–52.Google Scholar
  30. Schreck S, et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27(1):31–9.CrossRefPubMedGoogle Scholar
  31. Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology. 2009;126(2):165–76.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Takahama Y. Journey through the thymus: stromal guides for T-cell development and selection. Nat Rev Immunol. 2006;6(2):127–35.CrossRefPubMedGoogle Scholar
  33. Tangye SG et al. The good, the bad and the ugly – TFH cells in human health and disease. Nat Rev Immunol. 2013;13(6):412–26.Google Scholar
  34. Tran E et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–5.Google Scholar
  35. Trifari S, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10(8):864–71.CrossRefPubMedGoogle Scholar
  36. Weber J et al. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res. 2011;17(7):1664–73.Google Scholar
  37. Wen YJ, et al. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99(9):3280–5.CrossRefPubMedGoogle Scholar
  38. Xu X et al. Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression. Pancreas. 2014;43(3):470–7.Google Scholar
  39. Yoon NK et al. Higher levels of GATA3 predict better survival in women with breast cancer. Hum Pathol. 2010;41(12):1794–801.Google Scholar
  40. Zeng J et al. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int. 2013:658126.Google Scholar
  41. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445–89.Google Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Section of Surgical Oncology Research, Division of Surgical Oncology, Department of SurgeryRobert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations